Vaccination with a MHC class II peptide in Alum and inactive pertussis strongly ameliorates clinical MG in C57BL/6 mice

Journal of Neuroimmunology

Volumn 171, Issue 1-2, 2006, Pages 8-16

  Oshima, Minako ^a   Maruta, Takahiro ^a   Ohtani, Maki ^a   Deitiker, Philip R ^a   Mosier, Dennis R ^a,b   Atassi, M Zouhair ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antigen presentation; Autoimmunity; EAMG; Immunotherapy; MHC

Indexed keywords

ALANYLISOLEUCYLPHENYLALANYLLYSYLSERYLTYROSYLCYSTEINYLGLUTAMYLISOLEUCYL ISOLEUCYLVALYLTHREONYLHISTIDYLPHENYLALANYLPROLYLPHENYLALANYLASPARTIC ACID; ALUMINUM POTASSIUM SULFATE; ANTIBODY; ARGINYLGLYCYLTRYPTOPHYLLYSYLHISTIDYLTRYPTOPHYLVALYLTYROSYLTYROSYLTHREONYL CYSTEINYLCYSTEINYLPROLYLASPARTYLTHREONYLPROLYLTYROSINE; ASPARAGINYLSERYLGLUTAMINYLPROLYLGLUTAMYLISOLEUCYLLEUCYLGLUTAMYLARGINYL THREONYLARGINYLALANYLGLUTAMYLLEUCYLASPARTIC ACID; ASPARTYLTYROSYLTHREONYLGLYCYLLYSYLISOLEUCYLMETHIONYLTRYPTOPHYLTHREONYL PROLYLPROLYLALANYLISOLEUCYLPHENYLALANYLLYSYLSERINE; GLUTAMYLVALYLASPARAGINYLGLUTAMINYLISOLEUCYLVALYLGLUTAMYLTHREONYL ASPARAGINYLVALYLARGINYLLEUCYLARGINYLGLUTAMINYLGLUTAMINYLTRYPTOPHAN; HISTIDYLPHENYLALANYLPROLYLPHENYLALANYLASPARTYLGLUTAMINYLGLUTAMINYL ASPARAGINYLCYSTEINYLTHREONYLMETHIONYLLYSYLLEUCYLGLYCYLISOLEUCYLTRYPTOPHYL THREONINE; LEUCYLARGINYLGLUTAMINYLGLUTAMINYLTRYPTOPHYLISOLEUCYLASPARTYLVALYLARGINYL LEUCYLARGINYLTRYPTOPHYLASPARAGINYLPROLYLALANYLASPARTIC ACID; LEUCYLGLYCYLISOLEUCYLTRYPTOPHYLTHREONYLTYROSYLASPARTYLGLYCYLTHREONYLLYSYL VALYLSERYLISOLEUCYLSERYLPROLYLGLUTAMYLSERINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; PERTUSSIS VACCINE; PHENYLALANYLMETHIONYLGLUTAMYLSERYLGLYCYLGLUTAMYLTRYPTOPHYLVALYLMETHIONYL LYSYLASPARTYLTYROSYLARGINYLGLYCYLTRYPTOPHYLLYSYLHISTIDINE; SERYLGLUTAMYLHISTIDYLGLUTAMYLTHREONYLARGINYLLEUCYLVALYLALANYLASPARAGINYL LEUCYLLEUCYLGLUTAMYLASPARAGINYLTYROSYLASPARAGINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IMMUNIZATION; MOLECULE; MOUSE; MOUSE STRAIN; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ACTION POTENTIALS; ALUM COMPOUNDS; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PERTUSSIS VACCINE; PHYSICAL CONDITIONING, ANIMAL; RADIOIMMUNOASSAY; RECEPTORS, CHOLINERGIC; TORPEDO; VACCINATION;

EID: 29244482781     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2005.09.015     Document Type: Article

References (46)

1. M.Z. Atassi, and M. Oshima Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides Crit. Rev. Immunol. 17 1997 481 495
2. M.Z. Atassi, K.H. Ruan, K. Jinnai, M. Oshima, and T. Ashizawa Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide Proc. Natl. Acad. Sci. U. S. A. 89 1992 5852 5856
3. F.M. Audibert, and L.D. Lise Adjuvants: current status, clinical perspectives and future prospects Immunol. Today 14 1993 281 284
4. + cells sensitized to nicotinic acetylcholine receptor J. Immunol. 147 1991 1484 1491
5. P.W. Berman, and J. Patrick Experimental myasthenia gravis. A murine system J. Exp. Med. 151 1980 204 223
6. S. Berrih-Aknin, S. Cohen-Kaminsky, D. Neumann, D. Safar, B. Eymard, C. Gaud, P. Levasseur, S. Fuchs, and J.F. Bach Cellular aspects of myasthenia gravis Immunol. Res. 7 1988 189 199
7. C.R. Boughton Pertussis vaccines: acellular versus whole-cell Med. J. Aust. 164 1996 564 566
8. J.H. Brown, T.S. Jardetzky, J.C. Gorga, L.J. Stern, R.G. Urban, J.L. Strominger, and D.C. Wiley Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1 Nature 364 1993 33 39
9. T.L. Bugawan, G. Angelini, J. Larrick, S. Auricchio, G.B. Ferrarar, and H.A. Erlich A combination of a particular HLA-DP β allele and an HLA-DQ heterodimer confers susceptibility to coeliac disease Nature 339 1989 470 473
10. P. Christadoss, V.A. Lennon, C.J. Krco, and C.S. David Genetic control of experimental autoimmune myasthenia gravis in mice: III. Ia molecules mediate cellular immune responsiveness to acetylcholine receptors J. Immunol. 128 1982 1141 1144
11. P. Christadoss, J.M. Lindstrom, R.W. Melvold, and N. Talal Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis Immunogenetics 21 1985 33 38
12. D.H. Donaldson, M. Ansher, S. Horan, R.B. Rutherford, and S.P. Ringel The relationship of age to outcome in myasthenia gravis Neurology 40 1990 786 790
13. L.F. Fries, D.M. Gordon, R.L. Richards, J.E. Egan, M.R. Hollingdale, M. Gross, C. Silverman, and C.R. Alving Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy Proc. Natl. Acad. Sci. U. S. A. 89 1992 358 362
14. E. Harlow, and D. Lane Antibodies: A Laboratory Manual 1988 Cold Spring Harbor Laboratory New York 99
15. P. Hjelmstrom, R. Giscombe, A.K. Lefvert, R. Pirskanen, I. Kockum, M. Landin-Olsson, and C.B. Sanjeevi Polymorphic amino acid domains of the HLA-DQ molecules are associated with disease heterogeneity in myasthenia gravis J. Neuroimmunol. 65 1996 125 131
16. R. Hohlfeld, I. Kalies, B. Kohleisen, K. Heininger, B. Conti-Tronconi, and K.V. Toyka Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines Neurology 36 1986 618 621
17. R. Hohlfeld, K.V. Toyka, S.J. Tzartoss, W. Carson, and B. Conti-Tronconi Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor α subunit Proc. Natl. Acad. Sci. U. S. A. 84 1987 5379 5383
18. T. Horiki, H. Inoko, J. Moriuchi, Y. Ichikawa, and S. Arimori Combinations of HLA-DPB1 and HLA-DQB1 alleles determine susceptibility to early-onset myasthenia gravis in Japan Autoimmunity 19 1994 49 54
19. A.J. Infante, P.A. Thompson, K.A. Krolick, and K.A. Wall Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes J. Immunol. 146 1991 2977 2982
20. T.R. Johns Long-term corticosteroid treatment of myasthenia gravis Ann. N.Y. Acad. Sci. 505 1987 568 583
21. C.R. Kahn, K.R. McIntosh, and D.B. Drachman T-cell vaccination in experimental myasthenia gravis: a double-edged sword J. Autoimmun. 3 1990 659 669
22. T. Kanai, Y. Nomura, M. Segawa, K. Takagi, S. Senju, S. Matsushita, and Y. Nishimura Immuno-suppressive peptides for a human T cell clone autoreactive to a unique acetylcholine receptor alpha subunit peptide presented by the disease-susceptible HLA-DQ6 in infant-onset myasthenia gravis Hum. Immunol. 56 1997 28 38
23. P.I. Karachunski, N.S. Ostlie, D.K. Okita, and B.M. Conti-Fine Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences J. Clin. Invest. 100 1997 3027 3035
24. R.T. Kenney, D.L. Sacks, J.P. Sypek, L. Vilela, A.A. Gam, and K. Evans-Davis Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis J. Immunol. 163 1999 4481 4488
25. V.A. Lennon, D.J. McCormick, E.H. Lambert, G.E. Griesmann, and M.Z. Atassi Region of peptide 125-147 of acetylcholine receptor of α subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies Proc. Natl. Acad. Sci. U. S. A. 82 1985 8805 8809
26. J.M. Lindstrom, M.E. Seybold, V.A. Lennon, S. Whittingham, and D.D. Duane Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value Neurology 26 1976 1054 1059
27. J.L. McAnally, L. Xu, M. Villain, and J.E. Blalock The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis Exp. Biol. Med. 226 2001 307 311
28. D.J. McCormick, and M.Z. Atassi Localization and synthesis of the acetylcholine-binding site in the α-chain of the Torpedo californica acetylcholine receptor Biochem. J. 224 1984 995 1000
29. bm12 gene is evidence for genetic exchange between mouse immune response genes Nature 308 1984 551 553
30. N. Nagvekar, L. Corlett, L.W. Jacobson, H. Matsuo, R. Chalkley, P.C. Driscoll, S. Deshpande, E.G. Spack, and N. Willcox Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor J. Immunol. 162 1999 4079 4087
31. N. Nakayashiki, M. Oshima, P.R. Deitiker, T. Ashizawa, and M.Z. Atassi Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope J. Neuroimmunol. 105 2000 131 144
32. W. Ofosu-Appiah, F. Mokhtarian, D. Shirazian, and D. Grob Production of anti-acetylcholine receptor-α antibody in vitro by peripheral blood lymphocytes of patients with myasthenia gravis: role of immunoregulatory T cells and monocytes J. Lab. Clin. Med. 124 1994 231 241
33. b on binding with and antigen presentation of Torpedo acetylcholine receptor α chain peptide 146-162 J. Immunol. 154 1995 5245 5254
34. M. Oshima, A.R. Pachner, and M.Z. Atassi Profile of the regions of acetylcholine receptor α chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor Mol. Immunol. 31 1994 833 843
35. M. Oshima, P. Deitiker, T. Ashizawa, and M.Z. Atassi Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG Autoimmunity 35 2002 183 190
36. M. Oshima, M. Ohtani, P.R. Deitiker, R.G. Smith, D.R. Mosier, and M.Z. Atassi Suppression by mAbs against DQB1 peptides of in vitro proliferation of AChR-specific T cells from myasthenia gravis patients Autoimmunity 38 2005 161 169
37. A.R. Pachner, F.S. Kantor, B. Mulac-Jericevic, and M.Z. Atassi An immunodominant site of acetylcholine receptor in experimental myasthenia gravis mapped with T-lymphocyte clones and synthetic peptides Immunol. Lett. 20 1989 199 204
38. D.P. Richman, and M.A. Agius Treatment of autoimmune myasthenia gravis Neurology 61 2003 1652 1661
39. L.S. Rickman, D.M. Gordon, R. Wistar Jr., U. Krzych, M. Gross, M.R. Hollingdale, J.E. Egan, J.D. Chulay, and S.L. Hoffman Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine Lancet 337 1991 998 1001
40. J.S. Rosenberg, M. Oshima, and M.Z. Atassi B-cell activation in vitro by helper T cells specific to region α146-162 of Torpedo californica nicotinic acetylcholine receptor J. Immunol. 157 1996 3192 3199
41. M. Shenoy, M. Oshima, M.Z. Atassi, and P. Christadoss Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α146-162 of acetylcholine receptor Clin. Immunol. Immunopathol. 66 1993 230 238
42. L.J. Stern, J.H. Brown, T.S. Jardetzky, J.C. Gorga, R.G. Urban, J.L. Strominger, and D.C. Wiley Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide Nature 368 1994 215 221
43. J.A. Todd, H. Acha-Orbea, J.I. Bell, N. Chao, Z. Fronek, C.O. Jacob, M. McDermott, A.A. Sinh, L. Timmerman, L. Steinman, and H.O. McDevitt A molecular basis for MHC class II-associated autoimmunity Science 240 1988 1003 1009
44. A. Vincent Unravelling the pathogenesis of myasthenia gravis Nat. Rev., Immunol. 2 2002 797 804
45. T. Yokoi, B. Mulac-Jericevic, J. Kurisaki, and M.Z. Atassi T lymphocyte recognition of acetylcholine receptor: localization of the full T cell recognition profile on the extracellular part of the α chain of Torpedo californica acetylcholine receptor Eur. J. Immunol. 17 1987 1697 1702
46. H. Yoshikawa, K. Iwasa, K. Satoh, and M. Takamori FK506 prevents induction of rat experimental autoimmune myasthenia gravis J. Autoimmun. 10 1997 11 16